1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for Antibody Drug Conjugates (ADC) comprise of an active cytotoxic drug and an appropriate linker. The Drug-Linker Conjugates can expand the utility of monoclonal antibody (mAbs) and improve their potency and effectiveness. The site-specific conjugations of Drug-Linker to an antibody may involve genetic engineering of the mAb to introduce discrete, available cysteines or non-natural amino acids with an orthogonally-reactive functional group handle. These site-specific approaches not only increase the homogeneity of ADCs but also enable novel bio-orthogonal chemistries that utilize reactive moieties other than thiol or amine. The cytotoxic drug, monomethyl auristatin E (MMAE), is conjugated to the three trastuzumab variants using a protease cleavable linker and shows in vivo therapeutic efficacy.

Drug-Linker Conjugates for ADC Related Products (29):

Cat. No. Product Name Effect Purity
  • HY-15575
    VcMMAE 99.89%
    VcMMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
  • HY-101070
    SMCC-DM1 99.02%
    SMCC-DM1 is DM1 with a reactive linker SMCC to make antibody drug conjugate. DM1 (mertansine), a thiol-containing maytansinoid, is a potent microtubule-disrupting agent.
  • HY-15578
    McMMAF 99.58%
    Mc-MMAF is a protective group-conjugated MMAF.
  • HY-111012
    DBCO-(PEG)3-VC-PAB-MMAE Chemical 98.07%
    DBCO-(PEG)3-VC-PAB-MMAE is made by MMAE conjugated to DBCO-(PEG)3-vc-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
  • HY-100566
    SuO-Val-Cit-PAB-MMAE
    SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide SuO-Val-Cit-PAB.
  • HY-128711
    MAL-di-EG-Val-Cit-PAB-MMAF 98.56%
    MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F).
  • HY-100861
    C-11
    C-11 is a tubulysin-based drug-linker conjugate for ADC, displays cytotoxicity for carcinoma cell lines.
  • HY-111554
    AcLys-PABC-VC-Aur0101
    AcLys-PABC-VC-Aur0101 is a cleavable anti-CXCR4 drug-linker conjugates for ADC.
  • HY-100567
    MAL-di-EG-Val-Cit-PAB-MMAE 99.57%
    MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).
  • HY-100374
    Val-Cit-PAB-MMAE 99.83%
    Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide Val-Cit-PAB.
  • HY-13631E
    Deruxtecan 99.43%
    Deruxtecan, a toxin and linker moiety of DS-8201, is a drug-linker conjugate for antibody-drug conjugate (ADC) extracted from patent WO2017002776A1, compound 1.
  • HY-15741
    Mc-MMAE
    Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.
  • HY-12460
    SPDB-DM4
    SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4) via a SPDB linker, exhibiting potent anti-tumor activity.
  • HY-100874
    N3-PEG3-vc-PAB-MMAE 99.18%
    N3-PEG3-vc-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide N3-PEG3-vc-PAB.
  • HY-19812
    Acetylene-linker-Val-Cit-PABC-MMAE
    Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for ADC.
  • HY-19811
    Fmoc-Val-Cit-PAB-MMAE
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
  • HY-101141
    sulfo-SPDB-DM4
    sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4) via the sulfo-SPDB linker.
  • HY-15740
    Mc-MMAD 98.50%
    Mc-MMAD is a protective group (maleimidocaproyl)-conjugated MMAD. MMAD is a potent tubulin inhibitor. Mc-MMAD is a drug-linker conjugate for ADC.
  • HY-15750
    Cys-mcMMAD
    Cys-mcMMAD is a drug-linker conjugate for ADC. MMAD is a potent tubulin inhibitor.
  • HY-19813
    mDPR-Val-Cit-PAB-MMAE
    mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). mDPR-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.